Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02419677

Enrollment

Registered

2015-04-17

Start date

2010-01-31

Completion date

2014-12-31

Last updated

2015-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

radiofrequency ablation, cytokine-induced killer cells, colorectal cancer iver metastases

Brief summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with colorectal cancer liver metastases (CRCLM).

Detailed description

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with resectable CRCLM.

Interventions

PROCEDURERadiofrequency ablation

Radiofrequency ablation is performed percutaneously under CT/US guidance.

BIOLOGICALCytokine-induced killer cells

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients with histologically confirmed adenocarcinoma * Primary lesions (colorectal cancer) are resected * Must have undergone prior complete resection of the primary tumor; liver metastases * Must be resectable or accessible for radiofrequency ablation (Five or less lung metastases measuring 5 cm or smaller). * Serum bilirubin level of 2.0 mg/dl or less. * Performance status of 0 or 1. * Expected survival of 1 year or more. * Informed consent from the patient.

Exclusion criteria

* With extrahepatic metastases * With other neoplastic disease that is measurable or being treated other than colorectal cancer.

Design outcomes

Primary

Measure	Time frame	Description
Recurrence-free survival	One year	Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

Secondary

Measure	Time frame	Description
Adverse events	4 weeks	Adverse events related to RFA and CIK treatments.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026